Through Peer2Peer, we continuously create insightful video content with leading surgeons on the topics that are important to you. Watch past webinars, engaging video interviews with thought leaders in cataract and refractive surgery, interesting case studies, as well as clinical presentations from in-person events and congresses. If you would like to feature in a Peer2Peer video, please speak to your Rayner representative or contact omidriahcp@rayner.com
Interoperative miosis in a man with no history of α-blocker use
Patients with history of α-blocker usage: a side by side OMIDRIA/No OMIDRIA
Contralateral eye scope view of patient eyes with +2D hyperopia on tamsulosin
Learn why Dr. Visco uses OMIDRIA at her ASC to deliver a better experience to surgical patients.
Hear Dr. Walter share the benefits of OMIDRIA in both patient chair time and improved outcomes.
Listen to Dr. Silverstein discuss how maintaining pupil size during cataract surgery plays a key role in achieving a positive surgical experience and positive patient outcomes.
Learn about real world evidence studies that show lower rates of post-operative CME and why it makes sense to have OMIDRIA on board
See why Dr. Walter describes OMIDRIA as a great red-zone defense.
Dr. Silverstein discusses how OMIDRIA significantly reduced all 3 facets of IFIS in this real world study among male patients with a history of tamsulosin usage.
Drs Wiley and Hura share how OMIDRIA contributes to the art of refractive cataract surgery
Expanding the focus beyond the immediate intraoperative benefits of OMIDRIA
Listen to Drs Wiley and Hura discuss why they started using OMIDRIA and how implementing it has led to an improved surgical experience for patients, surgeons, and staff.
OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
This site is intended for US Physician educational purposes only, using scientific exchange around the OMIDRIA experience.
Rayner, the Rayner logo, OMIDRIA, the OMIDRIA logo, and OMIDRIAssure are proprietary marks of Rayner. ©2022 Rayner Group, all rights reserved. US-OM-2200071 12/22
